West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$314.77 USD
-1.73 (-0.55%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $315.11 +0.34 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$314.77 USD
-1.73 (-0.55%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $315.11 +0.34 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Zacks News
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Steady Rise in ESG Investing to Boost These 5 Stocks
by Sreoshi Bera
ESG investing will continue its northward momentum and this calls for investing in NVIDIA (NVDA), Microsoft (MSFT), EMCOR (EME), West Pharma (WST) and Texas Instruments (TXN)
West Pharmaceutical Services (WST) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.58% and 7.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
5 MedTech Stocks That Have Outperformed the Industry in 2020
by Debanjana Dey
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
Grab 3 Dental Stocks More Than Doubling Industry Gains for 2021
by Trina Mukherjee
Buy these three top dental stocks that have shown sharp recovery despite market volatility due to the pandemic, and have the potential to continue their bull run in 2021.
MCK vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Has West Pharmaceutical Services (WST) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Is West Pharmaceutical Services (WST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
COVID-19 Vaccine Rollout Challenges Put These Stocks in Focus
by Rimmi Singhi
With COVID-19 vaccine on the horizon, cold-chain storage stocks including TT, CARR and TMO; vial makers like GLW and WST; and logistic operators including UPS and FDX are set to hog the limelight.
Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.
Has West Pharmaceutical Services (WST) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.
Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y
by Zacks Equity Research
In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.
Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.
Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.
Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.
Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.
Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.
Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%
by Zacks Equity Research
Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Hologic (HOLX) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in fourth-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.